Download CURRICULUM VITAE - Granger Medical

CURRICULUM VITAE
Steven N. Gange, MD, FACS
Summit Urology Group
4252 South Highland Dr., Suite 200
Salt Lake City, UT 84124
Phone: (801) 993-1800
Fax: (801) 993-1711
EDUCATION
University of California, Riverside (UCR)
Bachelor of Science, Biomedical Sciences, 1983
High Honors
Claremont Men’s College, Pomona, CA
Army ROTC, Commissioned 2nd Lieutenant, 1982
Distinguished Military Student
UCLA School of Medicine
Medical Doctorate, 1986
PROFESSIONAL TRAINING
University of Kentucky, Albert B. Chandler Medical Center, Lexington, KY
Intern, General Surgery
1987
Resident, Urology
1987-90
Chief Resident, Urology
1991
POST-GRADUATE TRAINING
Army Medical Corps Officer Basic Course, Ft. Sam Houston, TX
7/91
Combat Casualty Care Course, Camp Bullis, TX
8/91
POST-GRADUATE TRAINING (continued)
Laparoscopy and Perineal Prostatectomy, San Francisco, CA
9/92
Transurethral Laser Procedures, San Francisco, CA
6/93
Microsurgery, Honolulu, HI
8/94
Critical Appraisal of Research Evidence, Honolulu, HI
6/95
Anatomic Radical Perineal Prostatectomy, Traverse City, MI
10/97
Understanding the CME Accreditation Process, Tempe, AZ
12/97
Prostate Brachytherapy, Phoenix, AZ
1/98
The Business of Medicine, 120 hr CME certificate course,
Johns Hopkins University, Salt Lake City, UT
9/98-7/99
Introduction to Clinical Quality Improvement, Salt Lake City, UT
4/00
Good Clinical Practices, Salt Lake City, UT
10/02
Surgical Treatment of ED with Penile Prosthesis Implantation
Van Buren, AK
6/03
Prostate and Renal Cryotherapy
Denver, CO
The Complete Course for Medical Staff Leaders
Phoenix, AZ
3/06
3/07
The Landmark Forum
Salt Lake City, UT
3/07
Landmark Advanced Course
Phoenix, AZ
5/07
High Intensity Focused Ultrasound (HIFU) for Prostate Cancer
Cancun, Mexico
4/09
Minimally Invasive Penile Implant
Miami, FL
4/10
UroLift for BPH: first Urologist trained in N America
2/11
Rezum for BPH: first Urologist trained in N America
1/13
BOARD CERTIFICATION
Diplomate, American Board of Urology
2/94
Certificate # 10696 (recertified Jan 2012, expires Feb 2024)
2
CURRENT ACADEMIC APPOINTMENT
Chief, Urology Clinical Instruction
2012
St Mark’s Family Medicine Residency
ACTIVE MEDICAL LICENSURE
Utah
# 96-322626-1205
DEA
# BG5029358
NPI
# 179825768
Grand Cayman Islands #MDC/PL/MED/387
1996
2015
MILITARY SERVICE
Major, Medical Corps, United States Army
Letterman U.S. Army Hospital, Presidio of San Francisco
8/91-4/93
Chief of Urology
Tripler Army Medical Center, Honolulu, HI
5/93-10/95
Chief, Urology Clinic
William Beaumont Army Medical Center, El Paso, TX
11/95-10/96
Chief, Urology Clinic
ACTIVE HOSPITAL STAFF APPOINTMENTS
St. Mark’s Hospital, Salt Lake City, UT
Chief of Surgery
Medical Staff Secretary/Treasurer
CME Program Founder
Committee Chairman
1996-present
2007-2009
1998-2001
Alta View Hospital, Sandy, UT
2006-present
Lone Peak Hospital, Draper, UT
2011-present
1997-2002
PROFESSIONAL SOCIETY MEMBERSHIPS
American Association of Clinical Urologists
1989
American Urological Association
Member, Practice Management Committee
1995
2008-2014
Fellow, American College of Surgeons
1995
3
PROFESSIONAL SOCIETY MEMBERSHIPS (continued)
Western Section, AUA
Member, Bylaws Committee
Chair, Bylaws Committee
Board Member
1996
2001-02
2003
2006-2008
Utah Medical Association
Member, State CME Committee
1996
1996-2009
American Medical Association
1997
Society of Urologic Prosthetic Surgeons
2006
Sexual Medicine Society of North America
2008
COMMUNITY SERVICE
American Cancer Society Volunteer
Numerous articles as Urology Expert for WebMD.com
Urology Expert for Q & A for UTHealth.com
1997-2003
1998-2001
1999-2006
Prostate Cancer (Man-To-Man) Facilitator Training
American Cancer Society, Salt Lake City, UT
2/99
Event Organizer and Program Coordinator
Men’s Health and Fitness Expo
Keynote Speaker: Sen. Bob Dole
2,000 attendees, Sen. Bob Dole Keynote Speaker
The E Center, West Valley City, UT
6/99
Founder and President, Utah Healthy Living Foundation
2000-present
Dedicated to improving the health and fitness of Utahans through
education and medical screenings
CME-Accredited as of June 2006, active
Founder and President, American Foundation for Healthy Living 2009
Co-Founder and Medical Director, UTHealth Magazine
2001-present
A monthly free publication; 40,000 copies distributed locally
Board Member, Utah HealthCare Institute
2002-2005
To improve the health and wellness of Utah communities,
with an emphasis on the under-served, by providing
quality health care and medical education
Speaking of Men’s Health (Volunteer Faculty)
2003-2004
4 and 5 Annual “Speaking of Women’s Health” Conference
Salt Palace, Salt Lake City, UT
th
th
4
COMMUNITY SERVICE (continued)
Utah Cancer Action Network Volunteer
Chairman
2004-present
2006-2007
Board Member, IVUmed
2009-2012
A non-profit education and membership organization, founded in
1995, to make quality urological care available to people worldwide.
Swaziland Male Circumcision Project
Swaziland, Africa
Jointly sponsored (USAID, CHIP, Jhpiego)
8/2010
LEADERSHIP
Class President, UCR-UCLA Biomedical Sciences
Cadet Battalion Commander, Army ROTC
House Staff President, UK Medical Center
Chair, CME Committee, St. Mark’s Hospital
Member, Utah Medical Association CME Committee
Chair, Prostate Cancer Task Force,
American Cancer Society, Salt Lake
Member, Utah State Council,
American Cancer Society
Medical Staff Secretary/Treasurer, St. Mark’s
Chief, Division of Urology, St. Mark’s Hospital
Co-Founder and President
Utah Healthy Living Foundation
Chief, Division of Urology, Cottonwood Hospital
Chair, Bylaws Committee, Western Section, AUA
Secretary-Treasurer
Utah Urological Society
President, Utah Urological Society
Chief, Department of Surgery, St. Mark’s
Vice-Chair, Utah Cancer Action Network
Chair, Utah Cancer Action Network
Board Member, Western Section AUA
Practice Management Committee Member, AUA
1979-86
1982-1983
1988-1989
1998-2003
1998-2009
1998-2003
1999-2003
1998-2001
1999-2002
2000-present
2003-2008
2003
2004-2005
2006-2007
2006-2008
2005-2006
2006-2007
2006-2008
2008-2014
AWARDS
MILITARY MEDALS
Army Service Ribbon
National Defense Service Medal
Meritorious Service Medal (twice awarded)
Overseas Service Medal
PERFORMANCE RECOGNITION
Outstanding Cadet, ROTC Basic Camp, Ft. Knox, KY
Outstanding ROTC Cadet, Los Angeles County
NIH Student Research Grant, UCLA
Surgical Intern of the Year, UK Medical Center
“Top Doctors in America” (voted by peers)
First ever UroLift Center of Excellence designee
1981
1982
1984
1987
1999-2003
11/2016
5
CLINICAL RESEARCH IN UROLOGY
Benign Prostatic Hypertrophy
A Phase III Study of the Efficacy and Safety of XXXXX in Subjects with
Symptomatic Benign Prostatic Hyperplasia (BPH).
A Phase III Study of the Efficacy and Safety of XXXXX in Subjects with
Symptomatic Benign Prostatic Hyperplasia (BPH).
A Long-Term, Open Label Extension Trial Evaluating the Safety and
Efficacy of XXXXX in Subjects with Benign Prostatic Hyperplasia (BPH)
A Double-Blind Placebo-Controlled, Parallel-Group Safety And Efficacy
Study Evaluating Three Dose Regimens Of XXXXX, A Selective AlphaAdrenergic Antagonist, In The Treatment of Benign Prostatic Hyperplasia
XXXX in patients with symptomatic BPH: an open-labeled safety and
efficacy assessment study (Principal Investigator)
Phase 3 multicenter, randomized, parallel-group, placebo-controlled,
double-blind clinical evaluation of XXXXX for the treatment of BPH.
(Principal Investigator)
Multicenter, randomized,double-blind clinical evaluation of XXXXX for the
treatment of BPH. (Principal Investigator)
Multicenter, randomized,double-blind clinical evaluation of XXXXX for the
treatment of BPH. (Principal Investigator)
Bladder Cancer
A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3
Trial of Single Dose Intravesical XXXXX as a Surgical Adjuvant Instilled
in the Early Postoperative Period in Patients Undergoing Transurethral
Resection for Noninvasive Bladder Cancer
Chronic Prostatitis
A Randomized, Double-Blind, Multicenter, Phase III Study Of XXXXX And
XXXXX In The Treatment Of Chronic Bacterial Prostatitis (Principal
Investigator)
Complicated Urinary Tract Infection
A Double-Blind, Multicenter, Parallel Group Study To Compare The
Efficacy And Safety Of Oral XXXXX 320mg Once Daily Versus Oral
XXXXX 250mg Once Daily For 10 Days In The Treatment Of
Pyelonephritis Or Complicated Urinary Tract Infections.
Erectile Dysfunction
Open-Label Study Of The Efficacy And Safety Of An Aqueous XXXXX
Topical Cream In The Treatment Of Erectile Dysfunction
6
CLINICAL RESEARCH IN UROLOGY (continued)
Erectile Dysfunction
Phase III, Efficacy And Safety Of An Aqueous XXXXX Topical Cream In
The Treatment Of Erectile Dysfunction.
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo
Controlled, Flexible Dose Escalation Study To Evaluate Self-Esteem And
Overall Relationships In Men With Erectile Dysfunction Treated With
XXXXX In The United States
HPV
A Study to Evaluate the Efficacy of XXXXX (Types 6, 11, 16 and 18) L1
Virus-Like Particle (VLP) Vaccine in Reducing the Incidence of HPV 6-,
11-, 16-, and 18-Related External Genital Warts, PIN, Penile, Perianal and
Perineal Cancer, and the Incidence of HPV 6-, 11-, 16-, and 18-Related
Genital Infection in Young Men
Nocturia
A Phase III, Placebo-Controlled, Pilot Study To Determine The Efficacy Of
XXXXX In The Treatment Of Nocturnal Symptoms Of Overactive Bladder
And Its Effects On Quality Of Sleep
Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo
Controlled, Multicenter Study to Assess the Efficacy and Safety of the
XXXXXX in Subjects with Symptoms of Overactive Bladder
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the XXXXX
in Subjects with Symptoms of Overactive Bladder
Prostate Cancer
A Phase III, Multicenter, Open-Label Randomized Study of XXXXX vs.
XXXXX In Patients with Prostate Cancer Who Are Candidates for Initial
Hormonal Therapy (Principal Investigator)
A Rollover, Multicenter, Open-Label, Maintenance Study of Patients with
Prostate Cancer Who Were Previously Treated with XXXXX 50 mg or 100
mg IM (Principal Investigator)
A Six-Month, Open-Label, Fixed-Dose Study To Evaluate The Safety,
Tolerance, Pharmacokinetics And Endocrine Efficacy Of Two Doses Of
XXXXX 22.5 Mg In Patients With Advanced Prostate Cancer
An Eight-Month, Open-Label, Fixed-Dose Study to Evaluate the Safety,
Tolerance, Pharmacokinetics, and Endocrine Efficacy of Two Doses of an
XXXXX Drug at 30 MG in Patients with Advanced Prostate Cancer.
7
CLINICAL RESEARCH IN UROLOGY (continued)
Prostate Cancer
A 12 Month, Open-Label, Fixed-Dosed Study To Evaluate The Safety,
Tolerance, Pharmacokinetics, And Endocrine Efficacy Of Two Doses Of
XXXXX 45 Mg In Patients With Advanced Prostate Cancer (Principal
Investigator)
A Two-Month, Open-Label, Non-Controlled, Fixed-Dose Study To
Evaluate The Safety, Tolerance, And Pharmacokinetics Of A Single
Monthly Dose Of XXXXX In Orchiectomized Subjects With Advanced
Prostate Cancer
A Six-Month, Two -Part, Sequential, Open-Label, Fixed-Dose Study To
Evaluate The Safety, Tolerance, Pharmacokinetics and Endocrine Efficacy
of Monthly Doses of XXXXX In Patients With Advanced Prostate
(Principal Investigator)
An Open-Label, Non-Controlled, Fixed-Dose, Sequential Dose-Ranging
Study To Evaluate The Safety, Tolerance, Pharmacokinetics And
Hormonal Efficacy Of Monthly Doses Of XXXXX In Patients With
Advanced Prostate Cancer.
An Open-Label, Non-Controlled, Fixed-Dose, Sequential Study To
Evaluate The Safety, Tolerance, Pharmacokinetics and Hormonal Efficacy
of Monthly Doses Of XXXXX Extended Release XXXXX in Patient's with
Advanced Prostatic Cancer
An Open-Label, Multi-Center, Ascending, Single Dose Study Investigating
the Pharmacokinetics, Pharmacodynamics and Safety of XXXXX in
Prostate Cancer Patients
An Open-Label, Multi-Center, Extension Study Investigating the LongTerm Safety and Tolerability of Repeat Doses of XXXXX in Prostate
Cancer Patients
An Open-Label Study to Evaluate the Feasibility of Switching to Treatment
with an LHRH Agonist Following 12 Weeks of Treatment with XXXXX in
Patients with Prostate Cancer (Principal Investigator)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the
Safety and Efficacy of XXXXX mg XXXXX in Men with Metastatic,
Hormone-Refractory Prostate Cancer (Principal Investigator)
A Phase III Extension Study to Evaluate the Safety of XXXXX mg XXXXX
in Men with Hormone-Refractory Prostate Cancer (Principal Investigator)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the
Safety and Efficacy of XXXXX mg XXXXX in Men with Non-Metastatic,
Hormone-Refractory Prostate Cancer (Principal Investigator)
8
CLINICAL RESEARCH IN UROLOGY (continued)
Prostate Cancer
A Phase III Extension Study to Evaluate the Safety of XXXXX mg XXXXX
in Men with Hormone-Refractory Prostate Cancer (Principal Investigator)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3
Study of XXXXXXX on Prolonging Bone Metastasis-Free Survival in Men
with Hormone-Refractory Prostate Cancer
A Randomized, Double-Blind, Multicenter Study of XXXXXX Compared
with Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in
Men with Hormone-Refractory Prostate Cancer
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of
the Efficacy and Safety of XXXXXX Administered Orally Once Daily for
Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
(Principal Investigator)
Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled
Trial To Assess The Safety And Efficacy Of XXXXX In Delaying The
Systemic Progression Of Prostate Cancer In Patients With Intermediate
To High Risk Of Recurrence With Rising Prostate Specific Antigen (PSA)
Levels After Prostatectomy, Prostatectomy And Radiotherapy, Or
Radiotherapy Alone For Localized Disease (Principal Investigator)
Phase III, Multicenter, Open-Label, Randomized Study Of XXXXX Vs.
XXXXX, In Patients With Prostate Cancer Who Are Candidates For Initial
Hormonal Therapy.
A Multicenter Study Of XXXXX In Patients With Prostate Cancer In Whom
GnRH Agonists Are Contraindicated (Principal Investigator)
An Open-label Comparison of Neoadjuvant Hormonal Therapy (NHT) With
XXXXX 100 mg IM or XXXXX 7.5 mg IM in Patients With Prostate Cancer
Planned to Undergo Brachytherapy or External-beam Radiation Therapy
(Principal Investigator)
A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the
Efficacy, Safety and Parmacokinetics of Two XXXXX Formulations
in Subjects with Prostatic Adenocarcinoma
A Phase 3, Open-Label, Multi-Center, Safety and Efficacay Study of XXXX
in Patients with Prostate Cancer
Prostatitis, Chronic Pelvic Pain
A Multi-Center, Double-Blind, Placebo-Controlled Investigation of XXXXX
in the Treatment of Subjects with Moderate to Severe Abacterial Chronic
Prostatitic/Chronic Pelvic Pain Syndrome
9
CLINICAL RESEARCH IN UROLOGY (continued)
Questionnaire
Anxiety Questionnaire In Men With Prostate Cancer
Uncomplicated Urinary Tract Infection
Prospective, Randomized, Double-Blind Multi-Center, Comparative Trial
To Evaluate The Efficacy And Safety Of XXXXX Once Daily Modified
Release XXX For 3 Days Versus Conventional XXXXX Tablets BID For 3
Days In The Treatment Of Patients With Uncomplicated Urinary Tract
(uUTI) Infections
Urology-Urge Urinary Incontinence
A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled,
Parallel Group Study of the Efficacy and Safety of Controlled
ReleaseXXXXX Versus XXXXX in the Treatment of Subjects with
Overactive Bladder
A Phase III Multi-Center, Open Label, Continuation Study Of The LongTerm Safety, Toleration, Compliance And Efficacy Of Controlled Release
XXXXX In Subjects With Overactive Bladder
A Phase IIIB Multi-Center, Double-Blind, Randomized, Placebo-Controlled,
Parallel Group Study o fXXXXXX in Subjects With Overactive Bladder,
Study XXXXXXX
Urology-Urinary Incontinence
Double-Blind, Placebo Controlled Study of XXXXX in Subjects with
Symptoms of Overactive Bladder of Urgency, Frequency and Urinary
Incontinence
Open-label Extension Study of Sustained Release XXXXX in Subjects with
Symptoms of Overactive Bladder
A Long-Term, Open Label, Multicenter Study of XXXXXX in Subjects With
Overactive Bladder
A Multicenter, Double-Blind, Placebo-Controlled Study of 20 mg, Twice
Daily XXXXX for 12 Weeks Followed by a 9-Month, Open-Label
Treatment Phase in
Patients with Overactive Bladder.
A Dose-Range Study to Evaluate XXXXX, XXXXX and XXXXX When
Administered to Female Subjects With Unstable Bladder Conditions
Women's Health-Interstitial Cystitis
A Placebo-Controlled Study of XXXXX for the Treatment of Interstitial
Cystitis (Principal Investigator)
10
CLINICAL RESEARCH SPONSORS
Abbott
Amgen
Atrix
Bristol Myers Squibb
Medarex
NeoTract
Nymox
Pharmacia
Sepracor
Therion
Aeterna Zentaris
Astellas
Bioniche
GlaxoSmithKline
Merck
Novartis
Oakwood
Praecis
Spectrum
Watson
Alza
Astra-Zeneca
Boehringer-Ingelheim
Lilly-Icos
Myriad
NxThera
Pfizer
Roche
TAP
Zenflow
ACADEMIC APPOINTMENTS
Clinical Instructor, Urology
Oak Knoll Naval Hospital, Oakland, CA
UCSF/ VA Medical Center, San Francisco, CA
1991-93
1992-93
Associate Professor, Surgery
University of Hawaii
1994-95
Clinical Instructor, Urology
University of Utah Physician’s Assistant Program
1996-2008
Chief, Clinical Instruction, Urology
St. Mark’s Hospital Family Practice Residency Program
1996-present
Adjunct Faculty, Family Practice
University of Utah
2002-08
CME PRESENTATIONS
Comparison of Two Techniques of Epithelialization of the BLERAM Flap 11/88
36th Kimbrough Urological Seminar, San Antonio, TX
Calculi in Transplanted Kidneys
37th Kimbrough Urological Seminar, Norfolk, VA
11/89
Calcified Renal Masses
Kentucky Urologic Seminar, Louisville, KY
4/90
Diagnosis and Treatment of Urinary Tract Infections
24th Annual Family Medicine and Primary Care Review, Lexington, KY
2/91
Prostate Cancer Screening
39th Kimbrough Urological Seminar, Baltimore, MD
12/91
Laser Physics, Laser Tissue Interaction, and Comparison of Laser
Surgical Techniques for the Prostate (CME)
Transurethral Laser Procedures, Honolulu, HI
Course Coordinator and Surgical Instructor for Animal Lab
8/93
11
CME PRESENTATIONS (continued)
Comparison of Laser Surgical Techniques for the Prostate
Transurethral Laser Procedures, Honolulu, HI
Course Coordinator and Surgical Instructor for Animal Lab
10/93
Urology for the Primary Care Provider
Branch Medical Clinic, Kaneohe Bay Marine Base, HI
9/94
Urology for the Primary Care Provider
Makalapa Health Clinic, Pearl Harbor, HI
1/95
Testicular Cysts: A Case Report and Review of the Literature
42nd Kimbrough Urological Seminar, Charleston, SC
1/95
Urology for the Primary Care Provider
L.B.J. Tropical Medical Center, Pago Pago, American Samoa
2/95
BPH Update 1995
Majuro Hospital, Majuro, Republic of the Marshall Islands
5/95
Prostate Update ’95
VA Medical Center, Honolulu, HI
7/95
A New Technique of Sutureless Vasovasostomy: Preliminary Report
43rd Kimbrough Urological Seminar, Washington, DC
11/95
Lasers in Urology
WBAMC Sixth Annual Basic Laser Course, El Paso, TX
3/96
Radical Perineal Prostatectomy
St. Mark’s Hospital Tumor Board, Salt Lake City, UT
12/96
PSA, BPH, and Prostate Cancer
Paracelsus Regional Medical Center, Salt Lake City, UT
3/97
Prostatic Intraepithelial Neoplasia
Munson Medical Center, Traverse City, MI
10/97
Prostate Cancer Update
Pioneer Valley Hospital, West Valley City, UT
11/97
Prostatic Intraepithelial Neoplasia
St. Mark’s Hospital Tumor Board, Salt Lake City, UT
11/97
Diagnosis and Treatment of Impotence
Talbert Westridge Clinic, Salt Lake City, UT
1/98
Bladder Cancer Update
Utah Tumor Registry Conference
West Valley City, UT
3/98
BPH Roundtable Discussion
Salt Lake City, UT
2/98, 4/98
12
CME PRESENTATIONS (continued)
St. Mark’s Annual Staff Retreat
9/98
Course Coordinator
Deer Valley, UT
Prostate Cancer Treatment Guidelines
Annual Intermountain Hematology-Oncology Update
Snowbird, UT
10/98
Men’s Health Issues
Uinta County Medical Society
Evanston, WY
3/99
BPH Update
Central Valley Family Medicine Residency Lecture
Provo, UT
3/99
BPH: Medical Management
Utah Pharmaceutical Association
Salt Lake City, UT
4/99
St. Mark’s Hospital Annual Staff Retreat
Course Coordinator
Deer Valley, UT
1999-2003
Erectile Dysfunction Update
Salt Lake City, UT
6/00
BPH and PSA Update
Boise, ID
10/00
BPH and PSA Update
Salt Lake City, UT
11/00
BPH and PSA Update
St. George, UT
4/02
ED Update
Internal Medicine Grand Rounds
St. Mark’s Hospital
Salt Lake City, UT
5/02
UTI Update
Salt Lake City, UT
6/02
Male Hypogonadism
Salt Lake City, UT
9/02
Male Hypogonadism
University of Utah Family Medicine Grand Rounds
Salt Lake City, UT
10/02
13
CME PRESENTATIONS (continued)
Andropause
Society for Urologic Nursing Association (SUNA)
Salt Lake City, UT
1/03
ED Update
2/03
Family Practice Grand Rounds
Alta View Hospital
Sandy, UT
The Aging Male
Family Practice Residency Lecture
St. Mark’s Hospital
Salt Lake City, UT
2/03
The Aging Male
“Recent Advances in the Management of Prostate Cancer”
Seattle, WA
3/03
Medical Management of Urge Incontinence
Urology Residency Lecture
Salt Lake City, UT
4/03
Overactive Bladder
Family Practice Residency Lecture
St. Mark’s Hospital
Salt Lake City, UT
4/03
Complications of Advanced Prostate Cancer Treatment
“Recent Advances in the Management of Prostate Cancer”
Tampa, FL
5/03
Advances in BPH Therapy
Utah Physician’s Assistant Society
Salt Lake City, UT
5/03
Erectile Dysfunction
Family Practice Residency Lecture
St. Mark’s Hospital
Salt Lake City, UT
6/03
Male Hypogonadism
Salt Lake City, UT
8/03
Medical Management of Overactive Bladder
Salt Lake City, UT
8/03
Medical Management of BPH
Salt Lake City, UT
11/03
BPH Symposium (Chair)
Local Urologists
2/04
14
Salt Lake City, UT
CME PRESENTATIONS (continued)
BPH Symposium (Chair)
Local Urologists
Denver, CO
3/04
Bone Health in Prostate Cancer
Man to Man Meeting, ACS
Salt Lake City, UT
3/04
Improving Quality of Care
Annual Symposium of the Utah Urological Society
Founder, CME Chair (and Course Chairman 2004-2007)
Member Education Committee 2004-present
Park City and Salt Lake City, UT
2004-present
ED Update-2005 and OAB Update-2006
2005-2006
Annual Pharmacology Conference, Utah Pharmacists Association
Salt Lake City, UT
Hypogonadism and ED
19th Annual Utah Physician’s Assistants CME Conference
Mesquite, NV
4/07
Medical and Surgical Management of OAB
19th Annual Utah Physician’s Assistants CME Conference
Mesquite, NV
4/07
Men’s Health Update
St. Mark’s Hospital
Salt Lake City, UT
6/09
Prostate Cancer Update
Lakeview Hospital Grand Rounds
Bountiful, UT
4/10
Prostate Cancer Update
St. Mark’s Hospital Tumor Board
Salt Lake City,
4/10
Sexual Dysfunction in Diabetic Males
Annual Meeting of Diabetic Educators of Utah
Sandy, UT
11/10
HIFU for Prostate Cancer
Prostate Cancer Research Institute Annual Conference
Los Angeles, CA
9/11
Focal HIFU for Prostate Cancer
Utah Urological Society Annual Meeting
Salt Lake City, UT
3/13
15
CME PRESENTATIONS (continued)
Natural History of BPH
BPH Consortium
Thomas Jefferson School of Public Health
Philadelphia, PN
5/13
Multicenter, Randomized, Controlled Blinded Study of the
Prostatic Urethral Lift: The L.I.F.T. Study
Western Section AUA
Monterey, CA
11/13
BPH Update
Annual Meeting of AANP
Salt Lake City, UT
2/14
BPH Procedural Update
Excellence in Urology
Park City, UT
2/16
BPH Panel Discussion
Men’s Health Update
Saratoga Springs,
8/16
New Technologies in LUTS Treatment
and Moderator for BPH Session
Annual Meeting of the Sexual Medicine Society of N America
Scottsdale, AZ
11/16
Western Urological/Summit Urology Group Journal Club
Organizer (2006) and Chairman (2006-present)
2006-present
I have also conducted hundreds of roundtable discussions on BPH, CaP,
OAB, ED, Hypogonadism, etc
CURRENT RESEARCH, CONSULTING AND/OR SPEAKER’S BUREAUS (FOR CME
DISCLOSURE)
NeoTract
NxThera
Nymox
Zenflow
\
16
PUBLICATIONS
Isenberg, S, McRee, W, Jedrzynski, M, Gange, SN, and Gange, SL
Effects of Sickle Cell Anemia on Conjunctival Oxygen Tension and
Temperature
Arch Intern Med, 147:67, 1987
Gange, SN, Sadove, B, and McRoberts, JW
Comparison of Two Techniques of Epithelialization of the BLERAM Flap
(abstract) Proceedings of the 36th Kimbrough Urological Seminar, 1988
Gange, SN, Lucas, B
Calculi in Transplanted Kidneys (abstract)
Proceedings of the 37th Kimbrough Urological Seminar, 1989
Gange, SN
Experience with Prostate Cancer Screening (abstract)
Proceedings of the 39th Kimbrough Urological Seminar, 1991
Evans, C, Gupta, M, Jajodia,P, Gange, SN, Juster, R, and Narayan, P
Predictors of Survival Time Following Hormonal Therapy in Patients with
Metastatic Carcinoma of the Prostate (abstract)
Proceedings of the 69th Annual Meeting of the Western Section of the AUA,
1993
Gange, SN, Heldman, L, and Yuill, S
Testicular Cysts: A Case Report and Review of the Literature (abstract)
Proceedings of the 42nd Kimbrough Urological Seminar, 1995
Gange, SN, Heldman, L, and Yuill, S
Testicular Cysts: A Case Report and Review of the Tripler Experience
Hawaii Med Journal, 54: 678, 1995
Gange, SN, Schweitzer, D, and Deshon, GE
A New Technique of Sutureless Vasovasostomy: Preliminary Report (abstract)
Proceedings of the 43rd Kimbrough Urological Seminar, 1995
Gange, SN, Schweitzer, D, and Deshon, GE
Electro-ejaculation in Sprague-Dawley Rats (abstract)
Proceedings of the 43rd Kimbrough Urological Seminar, 1995
Leventhal, E, Gange, SN, Jezior, J, Payne, C, and Deshon, GE
Lomafloxicin as Single Dose Prophylaxis of TRUS-guided Prostate Biopsy (abstract)
Proceedings of the 43rd Kimbrough Urological Seminar, 1995
Gange, SN, Childs, LC, Hopkins, SA, Richardson, SF, and Lin, KK
Immediate Benefit of Radical Perineal Prostatectomy Compared with Radical
Retropubic Prostatectomy (abstract)
Proceedings of the Western Section AUA Meeting, 8/2004
17
PUBLICATIONS (continued)
Hayes, JK, Hansen, RS, Rogers, CL, Stephenson, RA, Swallow, CT, Gange, SN
Short-Term Androgen Blockade, EBRT, and HDR Brachytherapy are Effective in the
Management of Locally Advanced Prostate Cancer (abstract)
ASTRO Proceedings, 10/2006
Barkin, J, Giddens, J, Incze, P, Casey, R, Richardson, S, Gange, SN
UroLift System for Relief of Prostate Obstruction Under Local Anesthesia
Can J Urol 19:2, 6217-6222, 2012.
Roehborn, CG, Rukstalis, DB, Gange SN, et al
Multi-Center Randomized Controlled Blinded Trial of the Prostatic Urethral Lift: The
L.I.F.T. Study (abstract)
Proceedings of the American Urological Association, 5/2013
Roehborn, CG, Gange SN, et al
Multi-Center Randomized Controlled Blinded Trial of the Prostatic Urethral Lift: The
L.I.F.T. Study
J Urol 190, 2161-2167, December 2013
Clarke, J (Gange, contributor)
Optimizing Population Health and Economic Outcomes: Innovative Treatment for
Benign Prostatic Hyperplasia (BPH)
Population Health Management Vol 16 Suppl 2 December 2013 S1-13
McVary, K, Gange, SN, et al
Sexual Effects of Prostatic Urethral LIFT
J Sex Med 11: 279. 2014
Shore, N, Freedman, S, Gange SN et al
Prospective Multi-Center Study Elucidating Patient Experience After Prostatic
Urethral Lift
Can J Urol 2:1, 7094-7101, 2014
Roehrborn, C, Rukstalis, D, Barkin, J, Gange SN, et al
Three Year Results of the Prostatic Urethral L.I.F.T. Study
J Urol 22:3 7772-7782, 2015
Can
Gange SN
UroLift: An efficacious and effective treatment that can be performed under topical
anesthesia without oral sedation
VideoJournalofProstheticUrology2:050,2015.
https://vimeo.com/vjpu/review/133106801/14f48812e4
Gange SN
Prostatic Urethral Lift (UroLift) Placement Under Topical Anesthesia (video)
Urology Times Y-Tube, June 3, 2016
McVary K, Gange SN, et al
Multi-Center Randomized Controlled Blinded Trial of Convective Water Vapor Energy
in the Treatment of LUTS Secondary to BPH
J Urol 195: 1529-38, May 2016
18
PUBLICATIONS (continued)
McVary K, Gange SN, et al
Erectile and Ejaculatory Function Preserved with Convective Water Vapor Energy
Treatment of LUTS Secondary to BPH: Randomized Controlled Study
J Sex Med 2016; 13: 924-933
Roehrborn C, Gange SN, et al
Four Year Results of the Prostatic Urethral L.I.F.T. Study
Proceedings of the American Urological Association, 5/2016
Gange S, Freedman S, Moseley W
One Year Results of a Prospective Study to Characterize Patient Experience
After Prostatic Urethral Lift. Proceedings of the Western Section of the AUA.
10/2016.
Gange S, Freedman S, Roehrborn C, McVary K.
Prostatic Urethral Lift Preserves Sexual Function: 4 Year Results from LIFT
Randomized Study. Proceedings of the 2016 Annual Fall Scientific Meeting of the
SMSNA. 11/2016.
19